Intech Investment Management LLC Has $4.32 Million Stock Holdings in Palomar Holdings, Inc. $PLMR

Intech Investment Management LLC trimmed its stake in Palomar Holdings, Inc. (NASDAQ:PLMR) by 54.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,005 shares of the company’s stock after selling 44,956 shares during the quarter. Intech Investment Management LLC’s holdings in Palomar were worth $4,320,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Royal Bank of Canada increased its position in Palomar by 49.1% during the first quarter. Royal Bank of Canada now owns 2,956 shares of the company’s stock worth $406,000 after buying an additional 974 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Palomar by 5.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,427 shares of the company’s stock worth $2,115,000 after purchasing an additional 791 shares during the last quarter. NewEdge Advisors LLC bought a new stake in Palomar in the 1st quarter valued at $66,000. United Services Automobile Association acquired a new position in Palomar in the 1st quarter valued at $223,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Palomar by 11.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 72,661 shares of the company’s stock worth $9,960,000 after buying an additional 7,754 shares during the period. 90.25% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Palomar

In related news, insider Jonathan Knutzen sold 281 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $128.04, for a total value of $35,979.24. Following the completion of the sale, the insider directly owned 27,579 shares of the company’s stock, valued at approximately $3,531,215.16. This represents a 1.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO T Christopher Uchida sold 783 shares of Palomar stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $128.04, for a total transaction of $100,255.32. Following the transaction, the chief financial officer directly owned 14,752 shares in the company, valued at $1,888,846.08. This represents a 5.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 58,999 shares of company stock valued at $7,253,229 in the last three months. Insiders own 3.70% of the company’s stock.

Palomar News Roundup

Here are the key news stories impacting Palomar this week:

• Positive Sentiment: Zacks Research raised FY2026 EPS to $9.00 (from $8.00) and boosted FY2027 to $9.60 and FY2028 to $12.60 — a sizeable multi‑year upgrade that implies stronger forward profitability. MarketBeat PLMR
• Positive Sentiment: Zacks lifted several near‑term quarterly estimates: Q1 2026 to $2.07 (from $1.89), Q2 2026 to $1.95 (from $1.87), and Q3 2026 to $2.67 (from $1.91). They also raised Q1–Q3 2027 quarterlies (Q1 2027 to $2.46, Q2 2027 to $2.30, Q3 2027 to $2.82), reflecting a consistent upward revision pattern. MarketBeat PLMR
• Neutral Sentiment: A Zacks feature summarizing Street views notes the average analyst price target implies roughly 36.2% upside for PLMR — a bullish signal for sentiment but not a guarantee of price moves. Wall Street Analysts Think Palomar Could Surge
• Negative Sentiment: Zacks trimmed its Q4 2026 estimate slightly to $2.30 from $2.34 — a modest downgrade that appears isolated versus broad upward revisions elsewhere. MarketBeat PLMR

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on PLMR shares. Weiss Ratings raised shares of Palomar from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, January 14th. Evercore initiated coverage on shares of Palomar in a report on Monday, February 9th. They issued an “outperform” rating and a $150.00 price objective for the company. JPMorgan Chase & Co. raised their target price on shares of Palomar from $155.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, February 23rd. Wall Street Zen cut Palomar from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, Keefe, Bruyette & Woods increased their price target on Palomar from $170.00 to $171.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 6th. Seven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Palomar presently has an average rating of “Buy” and an average price target of $163.00.

Palomar Trading Up 1.5%

NASDAQ PLMR opened at $123.71 on Monday. The company has a market cap of $3.30 billion, a P/E ratio of 17.23 and a beta of 0.46. The company has a fifty day simple moving average of $128.55 and a 200 day simple moving average of $123.21. Palomar Holdings, Inc. has a 12-month low of $107.75 and a 12-month high of $175.85.

Palomar (NASDAQ:PLMR) last released its quarterly earnings data on Wednesday, February 11th. The company reported $2.24 earnings per share for the quarter, beating analysts’ consensus estimates of $2.06 by $0.18. The firm had revenue of $253.36 million for the quarter, compared to analyst estimates of $204.58 million. Palomar had a net margin of 22.50% and a return on equity of 22.77%. The business’s quarterly revenue was up 62.7% compared to the same quarter last year. During the same period last year, the firm earned $1.52 earnings per share. Sell-side analysts predict that Palomar Holdings, Inc. will post 5.99 EPS for the current year.

Palomar Profile

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.